Ocugen Operating Margin Growth & History (OCGN)
Ocugen's operating margin was −1,425.70% for fiscal 2025.
View full Ocugen company overviewOcugen annual operating margin history
| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −1,425.70% | −75.34 pp |
| 2024 | 2024-12-31 | −1,350.36% | −264.69 pp |
| 2023 | 2023-12-31 | −1,085.67% | +2494.35 pp |
| 2022 | 2022-12-31 | −3,580.02% | — |
| 2020 | 2020-12-31 | −49,500.00% | — |
Ocugen quarterly operating margin
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −1,105.11% | −100.37 pp |
| Q1 2026 | 2026-03-31 | −1,163.67% | −184.53 pp |
| Q3 2025 | 2025-09-30 | −1,005.99% | +160.56 pp |
| Q2 2025 | 2025-06-30 | −1,004.73% | +349.25 pp |
| Q1 2025 | 2025-03-31 | −979.14% | +225.60 pp |
| Q4 2024 | 2024-12-31 | −1,811.52% | −993.56 pp |
| Q3 2024 | 2024-09-30 | −1,166.55% | −830.49 pp |
| Q2 2024 | 2024-06-30 | −1,353.99% | +3499.62 pp |
| Q1 2024 | 2024-03-31 | −1,204.73% | +2866.37 pp |
| Q4 2023 | 2023-12-31 | −817.96% | +1839.04 pp |
| Q3 2023 | 2023-09-30 | −336.06% | +5052.35 pp |
| Q2 2023 | 2023-06-30 | −4,853.61% | −1498.09 pp |
| Q1 2023 | 2023-03-31 | −4,071.11% | −265.11 pp |
| Q4 2022 | 2022-12-31 | −2,657.00% | — |
| Q3 2022 | 2022-09-30 | −5,388.41% | — |
| Q2 2022 | 2022-06-30 | −3,355.52% | — |
| Q1 2022 | 2022-03-31 | −3,806.00% | — |
| Q2 2020 | 2020-06-30 | −7,827.91% | — |
Ocugen operating margin trends
Over the last five fiscal years, Ocugen's operating margin increased from −49,500.00% to −1,425.70%, a change of +48074.30 percentage points. The latest reported quarter, Q2 2026, shows −1,105.11%.
What operating margin means
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
How operating margin is calculated
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ocugen source filings ↗Community posts
Ocugen receives provisional Bahamas clearance for OCU400 access pathway
Ocugen ($OCGN) received provisional approval and priority designation from the Bahamas’ Longevity and Regenerative Therapies Board for OCU400, its experimental gene therapy for retinitis pigmentosa. The company intends to supply the treatme ...